Cardiff Oncology (Cardiff Oncology) Days Sales Outstanding : 142.14 (As of Dec. 2023)

View and export this data going back to 1997. Start your Free Trial

What is Cardiff Oncology Days Sales Outstanding?

Cardiff Oncology's average Accounts Receivable for the three months ended in Dec. 2023 was $0.24 Mil. Cardiff Oncology's Revenue for the three months ended in Dec. 2023 was $0.16 Mil. Hence, Cardiff Oncology's Days Sales Outstanding for the three months ended in Dec. 2023 was 142.14.

The historical rank and industry rank for Cardiff Oncology's Days Sales Outstanding or its related term are showing as below:

CRDF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 63.97 Med: 189.54 Max: 617.47
Current: 313.24

During the past 13 years, Cardiff Oncology's highest Days Sales Outstanding was 617.47. The lowest was 63.97. And the median was 189.54.

CRDF's Days Sales Outstanding is ranked worse than
88.18% of 888 companies
in the Biotechnology industry
Industry Median: 72.105 vs CRDF: 313.24

Cardiff Oncology's Days Sales Outstanding declined from Dec. 2022 (506.51) to Dec. 2023 (142.14).

Cardiff Oncology Days Sales Outstanding Historical Data

The historical data trend for Cardiff Oncology's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiff Oncology Days Sales Outstanding Chart

Cardiff Oncology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

276.36

260.79

434.64

617.47

396.04

Cardiff Oncology Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															506.51	795.41	353.59	116.17	142.14

Competitive Comparison of Cardiff Oncology's Days Sales Outstanding

For the Biotechnology subindustry, Cardiff Oncology's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardiff Oncology's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Cardiff Oncology's Days Sales Outstanding falls into.

Cardiff Oncology Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Cardiff Oncology's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0.771	+	0.288)	/	2 )	/	0.488	*	365
=	0.5295					/	0.488	*	365
=	396.04

Cardiff Oncology's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0.198	+	0.288)	/	2 )	/	0.156	*	365 / 4
=	0.243					/	0.156	*	365 / 4
=	142.14

Cardiff Oncology (NAS:CRDF) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Cardiff Oncology Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Cardiff Oncology's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardiff Oncology (Cardiff Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardiff Oncology Inc (NAS:CRDF) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

XE7C:Germany

Address

11055 Flintkote Avenue, San Diego, CA, USA, 92121

Website

https://www.cardiffoncology.com

Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias.

Executives

Gary W Pace	director	C/O RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Fairooz Kabbinavar	officer: Chief Medical Officer	C/O TOCAGEN INC., 4242 CAMPUS POINT COURT, STE. 500, SAN DIEGO CA 92121
Mark Erlander	officer: Chief Scientific Officer	C/O TROVAGENE, INC., 11055 FLINTKOTE AVENUE, SUITE A, SAN DIEGO CA 92121
Lale White	director	310 GODDARD, SUITE 150, IRVINE CA 92618
James O Armitage	director	C/O TESARO, INC., 1000 WINTER ST., SUITE 3300, WALTHAM MA 02451
James E. Levine	officer: Chief Financial Officer	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Renee P Tannenbaum	director	9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
Tod Smeal	officer: Chief Scientific Officer	11055 FLINTKOTE AVENUE, SA DIEGO CA 92121
Katherine L Ruffner	officer: Chief Medical Officer	11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121
Mani Mohindru	director	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Rodney S Markin	director	C/O UNIVERSITY OF NEBR MEDICAL CENTER, 983135 NEBRASKA MEDICAL CENTER, OMAHA NE 68198-3135
Gary S Jacob	director
Vicki Kelemen	officer: Exec. VP and COO	11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121
John P Brancaccio	director	C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116